Please note, this tool is intended to help departments assess the resources necessary to safely and compliantly conduct the study in question. This includes consideration of whether or not the investigator has enough potential participants, appropriate staffing, facilities, and adequate funding. In order to avoid delays in study implementation it is strongly encouraged that study teams complete this form and get it approved and signed prior to submission to any central office. A copy of this checklist signed by both the PI AND Departmental Official (Chair/Director/Division Chief), and will be required to upload at the time of the CTA submission in TRAcs.
Email of individual completing this form:
* must provide value
A copy of the completed checklist will be sent to this address for signature.
Today's Date:
* must provide value
Today M-D-Y
Principal Investigator
* must provide value
Departmental Official:
* must provide value
(Chair / Division Chief)
Project Title
* must provide value
Please provide a short summary or description of the purpose of this study and your motivation for opening this study at UMass Chan:
* must provide value
Primary Study Coordinator Name:
* must provide value
Primary Study Coordinator Email
* must provide value
Department Administrator name:
* must provide value
Department Administrator email:
* must provide value
Sponsor Protocol No. (if applicable):
Protocol Version No. (if applicable):
Which IRB will this protocol be submitted to for approval?
* must provide value
UMass
CIRB (NCI)
WIRB
Advarra
Other
If other IRB, please specify:
* must provide value
Will this protocol be peer reviewed?
* must provide value
Yes
No
Will any other departments be involved in this research study?
* must provide value
Yes
No
If yes, indicate the collaborating department(s):
* must provide value
The expectation is that study teams have worked with the appropriate member of any collaborating department to ensure that the requirements of the protocol are feasible,. OCR and/or UMMH may request documentation of collaborating departments approval if necessary.
Do you intend to utilize services from the Department of Medicine Core (DOM Core)?
* must provide value
Yes
No
Do you intend to utilize services from the Cancer Research Office (CRO)?
* must provide value
Yes
No
Will the CRO be the primary coordinating team?
Yes
No
Will this study involve the following?
Which Health Alliance locations will be involved in the study?
Will any of the following ancillary review committees be needed for this protocol?
Primary Funding Source:
* must provide value
NIH
Other Federal
Internal UMass Funding
Industry
Foundation / Nonprofit
Other
Speedtype (Required for all Internally Funded Research):
Is the sponsor fully funding this study?
* must provide value
Yes
No
If no, who will be funding this study?
* must provide value
Observational or Interventional Study?
* must provide value
Observational
Interventional
Study Phase:
* must provide value
If other, explain:
* must provide value
Does this study involve patients under the age of 18?
* must provide value
Yes
No
Does this study involve healthy volunteers?
* must provide value
Yes
No
Total (maximum) accrual for study at UMass Chan:
* must provide value
How many patients have been identified with this diagnosis based on PI knowledge/estimation:
* must provide value
Please indicate # patients/appropriate period of time (e.g. 5 patients/week)
How many patients have been identified with this diagnosis based on a data lake query or other method:
* must provide value
Please indicate # patients/appropriate period of time (e.g. 5 patients/week)
Because this study is using the CRO, please provide how many patients have been identified with this diagnosis based on the cancer registry:
* must provide value
Please indicate # patients/appropriate period of time (e.g. 5 patients/week)
More information regarding the available recruitment resources at UMass Chan CCTS including "Just-in-Time Alert" (JITA) - Real Time Patient Recruitment Application, Data Lake Extraction, i2b2, etc, can be accessed here .
Anticipated duration patients will be on study, including follow-up:
* must provide value
Where will the study be conducted? (Check all that apply)
* must provide value
Which UMass Member Hospital location:
* must provide value
If other, please explain:
* must provide value
Will UMMH staff (other than IDS) require specific protocol training?
* must provide value
Yes
No
What specific protocol training will be required?
* must provide value
Do you intend to utilize any of the following for research purposes only?CCTS-202 .
* must provide value
If imaging services, list any non-routine imaging and which provider will be performing them.
* must provide value
If laboratory services, list any non-routine local labs.
* must provide value
If infusion center, list specific non-routine services, including how many infusions and over what length of time.
* must provide value
If 'other', please explain:
* must provide value
Will hospitalization be required as part of this research study?
* must provide value
Yes
No
Do not include hospital stays related to unanticipated emergencies or symptom management.
What specific service will the study subject be admitted to?
* must provide value
If yes, how long will subjects be hospitalized?
If yes, has the unit been made aware of the study?
Will any study specific drug(s)/biologic(s)/device(s) be used in this research (check all that apply):
* must provide value
Has the Investigational Drug Service (IDS) been made aware of this study?
Yes
No
If any drugs/biologics/devices will be used, does the UMass Chan Principal Investigator hold the IND/IDE?
* must provide value
Yes
No
If yes, specify:
* must provide value
Does the UMass Investigator have a current MCSR Researcher License?
* must provide value
Yes
No
The Massachusetts law, Title 105 CMR 700.009, requires that every principal investigator (PI) who is conducting research involving any drug must be covered by a Massachusetts Controlled Substances Registration (MCSR) research license. This means that drug research should not commence until a MCSR research license is obtained from the Massachusetts Department of Public Health (MDPH). here .
In which setting will the study drug, biologic, or device be administered (check all that apply):
* must provide value
If drug or biologic, please provide the route of administration:
* must provide value
if "Other", please specify:
* must provide value
If device, describe how the device will be transported, stored, utilized:
* must provide value
Is the device being provided by the sponsor at no cost?
* must provide value
Yes
No
Is the device being used off label?
* must provide value
Yes
No
Yes
No
Has the department approved the purchase of the device through UMMH and arranged for the appropriate Epic coding of the device?
* must provide value
Yes
No
Please upload the documentation for the Epic coding of the device.
* must provide value
If "No", you will not be able to proceed with your OnCore shell record build, negotiations, or move forward with accrual from an institutional perspective until this is resolved. Your department administrator will need to work with the study team in order to assist with this. This will likely include ensuring that there is a billing code for the device that may not already exist (as this is a research device).
What is the DRG or CPT code for the device:
* must provide value
Is this study considered gene and/or cell therapy?
* must provide value
Yes
No
Is this an urgent request?
* must provide value
Yes
No
Please provide a summary of the gene/cell therapy study, including why this study should be conducted at UMass Chan?
* must provide value
Please provide a list of possible side effects or adverse events and risks related to the proposed gene/cell therapy.
* must provide value
What clinical services would be needed to support any anticipated adverse events? Please provide a detailed list.
* must provide value
Please provide the following information for 4 individuals who you believe could be called upon to serve as external reviewers for this study. These individuals, to the best of your knowledge, should be free of conflicts of interest (including serving in any other capacity on this protocol).
* must provide value
The study team is not required to contact these individuals in advance. The Gene and Cell Therapy Advisory Committee will reach out to these individuals directly.
Please upload a copy of the study investigator brochure.
* must provide value
Please provide a copy of the study protocol.
* must provide value
Please provide a copy of the consent form (if available).
Are there any competing studies currently active at UMass Chan?
* must provide value
Yes
No
If yes, please explain:
* must provide value
How many active studies does the PI currently have?
* must provide value
How many studies is the primary coordinator working on?
* must provide value
Please provide a brief list of personnel who you anticipate will be working on this study team. This includes sub-investigators, coordinators, research assistants, and research nurses, AND the number of years of research experience for each team member. This is intended to help ensure appropriate staffing.
* must provide value
As a reminder, all clinical research that meets any of the following criteria must be entered into OnCore:
Has an external fund source. Uses or purchases a service from UMass Memorial Health Care or any of its affiliates, including UMass Memorial Medical Group. Has or requires registration on ClinicalTrials.gov (has a NCT number). Uses the UMass Center for Clinical and Translational Science Clinical Research Center. Uses the services of the UMass IRB or Investigational Drug Services. Flags patients in Epic or uses Epic for recruitment. Requires access to https://www.conqueringdiseases.org/ recruitment tools. Please provide the names of the staff members who will be responsible for entry of data into OnCore.
* must provide value
Upon submission, a copy of this checklist will be provided to the individual completing this form (as completed above). The study team will be required to upload a copy signed by both the Principal Investigator AND departmental Chair/Division Chief at the time of the CTA submission in TRAcs .
Signatures can be collected via DocuSign
PI Name:
* must provide value
By signing this form you are acknowledging that the information contained in this form is accurate.
Departmental Chair / Division Chief Name:
* must provide value
By signing this form you are acknowledging that the information contained in this form is accurate and that this protocol is approved to move forward by the department/division.
Submit
Save & Return Later
Working...